DrugPatentWatch Database Preview
FORFIVO XL Drug Profile
Which patents cover Forfivo Xl, and what generic alternatives are available?
This drug has one patent family member in one country.
The generic ingredient in FORFIVO XL is bupropion hydrochloride. There are thirty-eight drug master file entries for this compound. Seventy-six suppliers are listed for this compound. Additional details are available on the bupropion hydrochloride profile page.
Summary for FORFIVO XL
| International Patents: | 1 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 2 |
| Bulk Api Vendors: | 92 |
| Patent Applications: | 814 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | see details |
| DailyMed Link: | FORFIVO XL at DailyMed |
Pharmacology for FORFIVO XL
| Drug Class | Aminoketone |
| Mechanism of Action | Dopamine Uptake Inhibitors Norepinephrine Uptake Inhibitors |
| Physiological Effect | Increased Dopamine Activity Increased Norepinephrine Activity |
Synonyms for FORFIVO XL
| ( inverted question mark)-1-(3-Chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone hydrochloride |
| (.+-.)-2-(tert-Butylamino)-3'-chloropropiophenone hydrochloride |
| (+-)-2-(tert-Butylamino)-3'-chloropropiophenone hydrochloride |
| (+-)-alpha-tert-Butylamino-3-chloropropiophenone hydrochloride |
| (+/-)-1-(3-Chlorophenyl)-2- [(1,1-dimethylethyl)amino]- 1-propanone hydrochloride |
| (+/-)-1-(3-Chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone hydrochloride |
| (+/-)-2-(t-butylamino)-3'-chloropropiophenone hydrochloride |
| 1-(3-CHLOROPHENYL)-2-[(1,1-DIMETHYLETHYL)AMINO]-1-PROPANE, MONOHYDROCHLORIDE |
| 1-(3-CHLOROPHENYL)-2-[(1,1-DIMETHYLETHYL)AMINO]-1-PROPANONE HYDROCHLORIDE |
| 1-Propanone, 1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)-, hydrochloride, (+-)- |
| 1-Propanone,1-dimethylethyl)amino]-, hydrochloride, (.+-.)- |
| 2-(tert-Butylamino)-1-(3-chlorophenyl)-1-propanone Hydrochloride |
| 2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one HCl |
| 2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one hydrochloride |
| 2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one;hydrochloride |
| 2-(tert-Butylamino)-3'-chloropropiophenone hydrochloride |
| 31677-93-7 |
| 34841-36-6 |
| 4CH-007122 |
| 77B937 |
| A820950 |
| AB0012179 |
| AB02273 |
| AB2000567 |
| AC-196 |
| AC1L1XZA |
| ACM34841366 |
| AK-75760 |
| AKOS015844544 |
| alpha-(tert-Butylamino)-m-chloropropiophenone hydrochloride |
| AM20060780 |
| Amfebutamon hydrochlorid |
| Amfebutamon hydrochloride |
| Amfebutamone (Bupropion) HCl |
| Amfebutamone hydrochloride |
| Amfebutamone(Bupropion) |
| AN-16061 |
| ANW-42367 |
| API0001440 |
| AX8118984 |
| B3649 |
| BC208314 |
| BCP0726000049 |
| BCP9000462 |
| BG0117 |
| Bio-0883 |
| Budeprion |
| Budeprion XL |
| Budeprion XL 300 |
| Bupropion (hydrochloride) |
| Bupropion Hcl |
| Bupropion hydrochloride |
| Bupropion hydrochloride (JAN/USP) |
| Bupropion hydrochloride [USAN:USP:JAN] |
| Bupropion hydrochloride [USAN:USP] |
| Bupropion Hydrochloride 1.0 mg/ml in Methanol (as free base) |
| Bupropion hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material |
| Bupropion hydrochloride, >=98% (HPLC), solid |
| Bupropion Hydrochloride, pharmaceutical secondary standard; traceable to USP |
| Bupropion hydrochloride, United States Pharmacopeia (USP) Reference Standard |
| Bupropion hydrocloride |
| BW 323 |
| BW-323 |
| BW-323U66 |
| CAS-31677-93-7 |
| CCG-100911 |
| CCG-39085 |
| CHEBI:3220 |
| CHEMBL1698 |
| CPD000058423 |
| CPI-300 |
| CS-2503 |
| CTK8B3357 |
| D00817 |
| DSSTox_CID_24561 |
| DSSTox_GSID_44561 |
| DSSTox_RID_80314 |
| DTXSID6044561 |
| EINECS 250-759-9 |
| EINECS 252-243-9 |
| EU-0100166 |
| FT-0081218 |
| FT-0623288 |
| HEYVINCGKDONRU-UHFFFAOYSA-N |
| HMS1568B20 |
| HMS1922F09 |
| HSDB 6988 |
| HY-B0403A |
| I06-0019 |
| I06-19 |
| J10311 |
| Jsp005899 |
| KB-224632 |
| KS-00000XL2 |
| KS-1034 |
| LP00166 |
| LS-125089 |
| M-5146 |
| m-Chloro-alpha-tert-butylaminopropionphenone hydrochloride |
| m-Chloro-alpha-tert-butylaminopropiophenone hydrochloride |
| MFCD00055209 |
| MLS000069376 |
| MLS001401370 |
| MLS002320678 |
| NC00161 |
| NCGC00015122-11 |
| NCGC00016807-01 |
| NCGC00093650-01 |
| NCGC00093650-02 |
| NCGC00093650-03 |
| NCGC00093650-04 |
| NCGC00093650-05 |
| NCGC00180895-01 |
| NCGC00180895-02 |
| NCGC00255927-01 |
| NCGC00260851-01 |
| NSC 315851 |
| NSC-315851 |
| NSC-758686 |
| NSC315851 |
| NSC758686 |
| OR147496 |
| Pharmakon1600-01504174 |
| Prestwick_668 |
| Propiophenone, 2-(tert-butylamino)-3'-chloro-, hydrochloride, (+-)- |
| Propiophenone, hydrochloride, (.+-.)- |
| PubChem20752 |
| Quomem |
| S2452 |
| SAM001246723 |
| SC-12179 |
| SCHEMBL41602 |
| SMR000058423 |
| SMR001338824 |
| SPECTRUM1504174 |
| ST24027672 |
| TC-010273 |
| Tox21_110621 |
| Tox21_110621_1 |
| Tox21_301844 |
| Tox21_500166 |
| V2047 |
| Voxra |
| Wellbutrin |
| Wellbutrin (TN) |
| Wellbutrin Retard |
| Wellbutrin SR |
| Wellbutrin XL |
| Wellbutrin XR |
| Wellbutrin;Zyban;Voxra;Budeprion;Aplenzin;Bupropion |
| Zyban |
| Zyban (pharmaceutical) |
| Zyban (TN) |
US Patents and Regulatory Information for FORFIVO XL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alvogen | FORFIVO XL | bupropion hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 022497-001 | Nov 10, 2011 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Paragraph IV (Patent) Challenges for FORFIVO XL
| Drugname | Dosage | Strength | RLD | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Tablets | 450 mg | ➤ Subscribe | 2013-02-28 |
Non-Orange Book US Patents for FORFIVO XL
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 8,703,191 | Controlled-release pharmaceutical tablets | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for FORFIVO XL
| Country | Document Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2008038155 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for FORFIVO XL
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 0918 | Netherlands | ➤ Sign Up | PRODUCT NAME: NALTREXON OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER NALTREXONHYDROCHLORIDE, EN BUPROPION OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER BUPROPIONHYDROCHLORIDE; REGISTRATION NO/DATE: EU/1/14/988 20150330 |
| /2000 | Austria | ➤ Sign Up | PRODUCT NAME: BUPROPION HYDROCHLORID; NAT. REGISTRATION NO/DATE: 1-23680 20000616; FIRST REGISTRATION: NL 24160 19991201 |
| 2017000109 | Germany | ➤ Sign Up | PRODUCT NAME: NALTREXON ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE NALTREXONHYDROCHLORID, UND BUPROPION ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE BUPROPIONHYDROCHLORID; REGISTRATION NO/DATE: EU/1/14/988 20150326 |
| 2017 00062 | Denmark | ➤ Sign Up | PRODUCT NAME: NALTREXON ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER NALTREXONHYDROCHLORID, OG BUPROPION ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER BUPROPIONHYDROCHLORID; REG. NO/DATE: EU/1/14/988 20150330 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
